Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer

Immunology Letters

Volumn 116, Issue 1, 2008, Pages 7-14

  Gross, Stefanie ^a   Walden, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Cancer immunotherapy; DC; Immunosuppression; T cell; Tregs; Tumor angiogenesis; Tumor immunology; Tumor microenvironment; Tumor stroma

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CROSS-PRIMING; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR ESCAPE;

EID: 38549167908     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.11.012     Document Type: Review

References (106)

1. Lanier L. Missing self, NK cells, and the white album. J Immunol 174 (2005) 6565
2. Lanier L. A renaissance for the tumor immunosurveillance hypothesis. Nat Med 7 (2001) 1178-1180
3. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M., and Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 18 (2006) 151-158
4. Albertsson P., Basse P., Hokland M., Goldfarb R., Nagelkerke J., Nannmark U., et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24 (2003) 603-609
5. Le Maux Chansac B., Moretta A., Vergnon I., Opolon P., Lécluse Y., Grunenwald D., et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 175 (2005) 5790-5798
6. Parmiani G., and Anichini A. T cell infiltration and prognosis in HCC patients. J Hepatol 45 (2006) 178-181
7. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102 (2005) 18538-18543
8. Bodey B., Bodey B., Siegel S., and Kaiser H. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors. Anticancer Res 20 (2000) 1759-1768
9. Gattinoni L., Powell D., Rosenberg S., and Restifo N. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 (2006) 383-393
10. Effros R., and Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?. Immunol Today 18 (1997) 450-454
11. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
12. Wang H., and Wang R. Regulatory T cells and cancer. Curr Opin Immunol 19 (2007) 217-223
13. Grossman W., Verbsky J., Tollefsen B., Kemper C., Atkinson J., and Ley T. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104 (2004) 2840-2848
14. Grossman W., Verbsky J., Barchet W., Colonna M., Atkinson J., and Ley T. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004) 589-601
15. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20 (2004) 107-118
16. Curiel T., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
17. Gao Q., Qiu S., Fan J., Zhou J., Wang X., Xiao Y., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25 (2007) 2586-2593
18. + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006) 2866-2872
19. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98 (2003) 1089-1099
20. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61 (2001) 4766-4772
21. Barnett B., Kryczek I., Cheng P., Zou W., and Curiel T. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
22. Dannull J., Su Z., Rizzieri D., Yang B., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
23. Attia P., Maker A., Haworth L., Rogers-Freezer L., and Rosenberg S. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 (2005) 582-592
24. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
25. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126 (1999) 112-120
26. Koopman L., Corver W., van der Slik A., Giphart M., and Fleuren G. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191 (2000) 961-976
27. Kageshita T., Hirai S., Ono T., Hicklin D., and Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154 (1999) 745-754
28. de Vries T., Fourkour A., Wobbes T., Verkroost G., Ruiter D., and van Muijen G. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57 (1997) 3223-3229
29. Hallermalm K., De Geer A., Kiessling R., Levitsky V., and Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 64 (2004) 6775-6782
30. Roth W., Isenmann S., Nakamura M., Platten M., Wick W., Kleihues P., et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61 (2001) 2759-2765
31. Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112 (1998) 166-171
32. Tsutsumi S., Kuwano H., Shimura T., Morinaga N., Mochiki E., and Asao T. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 89 (2000) 2560-2564
33. Sheen-Chen S., Chen H., Eng H., and Chen W. Circulating soluble Fas in patients with breast cancer. World J Surg 27 (2003) 10-13
34. Kondera-Anasz Z., Mielczarek-Palacz A., and Sikora J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis 10 (2005) 1143-1149
35. Gorter A., and Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20 (1999) 576-582
36. Bellone G., Smirne C., Mauri F., Tonel E., Carbone A., Buffolino A., et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55 (2006) 684-698
37. Toi M., Kondo S., Suzuki H., Yamamoto Y., Inada K., Imazawa T., et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77 (1996) 1101-1106
38. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., and Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14 (2005) 425-431
39. Huang M., Stolina M., Sharma S., Mao J., Zhu L., Miller P., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58 (1998) 1208-1216
40. Sombroek C., Stam A., Masterson A., Lougheed S., Schakel M., Meijer C., et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168 (2002) 4333-4343
41. 2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol 10 (2003) 455-462
42. 2 secretion in patients with breast cancer. Ann Surg Oncol 11 (2004) 328-339
43. Sánchez-Rovira P., Jimenez E., Carracedo J., Barneto I., Ramirez R., and Aranda E. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. Eur J Cancer 34 (1998) 394-398
44. Haskó G., Pacher P., Deitch E., and Vizi E. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 113 (2007) 264-275
45. Link A., Kino T., Worth J., McGuire J., Crane M., Chrousos G., et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 164 (2000) 436-442
46. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., and Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67 (2007) 2912-2915
47. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 (1996) 1363-1366
48. Bennett M., O'Connell J., O'Sullivan G., Brady C., Roche D., Collins J., et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160 (1998) 5669-5675
49. Stillman B., Hsu D., Pang M., Brewer C., Johnson P., Liu F., et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176 (2006) 778-789
50. Zubieta M., Furman D., Barrio M., Bravo A., Domenichini E., and Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168 (2006) 1666-1675
51. Toscano M., Commodaro A., Ilarregui J., Bianco G., Liberman A., Serra H., et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 176 (2006) 6323-6332
52. Rubinstein N., Ilarregui J., Toscano M., and Rabinovich G. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64 (2004) 1-12
53. Nakabayashi H., Nakashima M., Hara M., Toyonaga S., Yamada S., Park K., et al. Clinico-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape. Cancer Lett 246 (2007) 182-189
54. Fukuda K., Tsujitani S., Maeta Y., Yamaguchi K., Ikeguchi M., and Kaibara N. The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5 (2002) 220-227
55. Mueller M., and Fusenig N. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4 (2004) 839-849
56. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66 (2006) 1123-1131
57. Nouri-Shirazi M., Banchereau J., Bell D., Burkeholder S., Kraus E., Davoust J., et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 165 (2000) 3797-3803
58. Andre F., Schartz N., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360 (2002) 295-305
59. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25 (2007) 2546-2553
60. Ochoa A., Zea A., Hernandez C., and Rodriguez P. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13 (2007) 721s-726s
61. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006) 53-65
62. Brito C., Naviliat M., Tiscornia A., Vuillier F., Gualco G., Dighiero G., et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 162 (1999) 3356-3366
63. Masri F., Comhair S., Koeck T., Xu W., Janocha A., Ghosh S., et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 172 (2005) 597-605
64. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252 (2007) 86-92
65. Zeni E., Mazzetti L., Miotto D., Lo Cascio N., Maestrelli P., Querzoli P., et al. Macrophage expression of IL-10 is a prognostic factor in non-small cell lung cancer. Eur Respir J (2007)
66. + T-cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 118 (2006) 1909-1914
67. Zeidler R., Eissner G., Meissner P., Uebel S., Tampé R., Lazis S., et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90 (1997) 2390-2397
68. Zhang G., and Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19 (1999) 1427-1432
69. Mouawad R., Khayat D., Merle S., Antoine E., Gil-Delgado M., and Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?. Melanoma Res 9 (1999) 181-188
70. Aoe T., Okamoto Y., and Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181 (1995) 1881-1886
71. Kono K., Ressing M., Brandt R., Melief C., Potkul R., Andersson B., et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2 (1996) 1825-1828
72. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
73. Polak M., Borthwick N., Gabriel F., Johnson P., Higgins B., Hurren J., et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96 (2007) 1879-1887
74. + T cells. Blood 105 (2005) 1574-1581
75. 2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell-stimulatory capacity despite IDO. J Leukoc Biol 82 (2007) 1106-1114
76. s cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-243
77. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
78. Brizel D., Scully S., Harrelson J., Layfield L., Bean J., Prosnitz L., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
79. Rofstad E., Sundfør K., Lyng H., and Tropé C. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83 (2000) 354-359
80. Rofstad E., and Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 80 (1999) 1697-1707
81. Sonveaux P., Brouet A., Havaux X., Grégoire V., Dessy C., Balligand J., et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63 (2003) 1012-1019
82. Bouzin C., and Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 10 (2007) 109-120
83. Hussein M. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 87 (2006) 163-176
84. Varney M., Johansson S., and Singh R. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 15 (2005) 417-425
85. Greenwald R., Freeman G., and Sharpe A. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
86. Carreno B., and Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20 (2002) 29-53
87. + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104 (2007) 3360-3365
88. Nakanishi J., Wada Y., Matsumoto K., Azuma M., Kikuchi K., and Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56 (2007) 1173-1182
89. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X., and Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108 (2006) 19-24
90. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (2006) 190-198
91. + T cells leads to reversible immune dysfunction. Nat Med 12 (2006) 1198-1202
92. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80 (2006) 11398-11403
93. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81 (2007) 4215-4225
94. Thompson R., Dong H., Lohse C., Leibovich B., Blute M., Cheville J., et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13 (2007) 1757-1761
95. Flies D., and Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 30 (2007) 251-260
96. Kryczek I., Wei S., Zhu G., Myers L., Mottram P., Cheng P., et al. Relationship between B7-H4, regulatory T Cells, and patient outcome in human ovarian carcinoma. Cancer Res 67 (2007) 8900-8905
97. Miyatake T., Tringler B., Liu W., Liu S., Papkoff J., Enomoto T., et al. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106 (2007) 119-127
98. Wang X., Chen Y., Wang Q., Ge Y., Dai Q., Yang K., et al. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. Tissue Antigens 69 (2007) 145-153
99. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (2006) 1169-1177
100. Egen J., Kuhns M., and Allison J. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3 (2002) 611-618
101. Bhatia S., Edidin M., Almo S., and Nathenson S. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett 104 (2006) 70-75
102. Chambers C., Kuhns M., Egen J., and Allison J. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19 (2001) 565-594
103. Ribas A., Camacho L., Lopez-Berestein G., Pavlov D., Bulanhagui C., Millham R., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675. 206. J Clin Oncol 23 (2005) 8968-8977
104. Attia P., Phan G., Maker A., Robinson M., Quezado M., Yang J., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
105. Thompson R., Allison J., Kwon E., and Anti-cytotoxic. T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 24 (2006) 442-447
106. Maker A., Yang J., Sherry R., Topalian S., Kammula U., Royal R., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29 (2006) 455-463